Harrow Health (HROW) Given Consensus Recommendation of “Strong Buy” by Brokerages

Shares of Harrow Health (NASDAQ:HROW) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $11.38 for the company and are predicting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Harrow Health an industry rank of 157 out of 256 based on the ratings given to its competitors.

A number of equities analysts have recently commented on the stock. ValuEngine raised shares of Harrow Health from a “sell” rating to a “hold” rating in a report on Monday, May 13th. TheStreet raised shares of Harrow Health from a “d-” rating to a “c” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research downgraded shares of Harrow Health from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th.

Harrow Health stock traded down $0.09 during mid-day trading on Friday, reaching $6.38. The company had a trading volume of 363,943 shares, compared to its average volume of 249,182. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.43 and a quick ratio of 3.22. Harrow Health has a 52 week low of $1.99 and a 52 week high of $7.20. The company has a market cap of $158.10 million, a PE ratio of 10.41 and a beta of -0.02.

Harrow Health (NASDAQ:HROW) last issued its quarterly earnings results on Tuesday, March 12th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.07). Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The company had revenue of $11.38 million during the quarter, compared to the consensus estimate of $10.92 million. Analysts expect that Harrow Health will post -0.1 earnings per share for the current fiscal year.

In other news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $4.77, for a total transaction of $47,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 30,000 shares of company stock valued at $162,500 over the last ninety days. 12.43% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new position in shares of Harrow Health during the 1st quarter worth about $77,000. Jane Street Group LLC bought a new position in shares of Harrow Health during the 1st quarter worth about $87,000. Citigroup Inc. bought a new position in shares of Harrow Health during the 1st quarter worth about $92,000. FineMark National Bank & Trust acquired a new stake in shares of Harrow Health during the 1st quarter worth about $113,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in shares of Harrow Health during the 1st quarter worth about $125,000. 32.15% of the stock is owned by institutional investors.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: What is the yield curve?

Get a free copy of the Zacks research report on Harrow Health (HROW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.